Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study

Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. The primary outcome of this observational study is the comprehensive immunological cellular characterization during the AIT initiation phase, whereas the secondary outcomes are the serological and Th2-cell-type-specific transcriptomic analyses. Here we apply a multilayer-omics approach to reveal dynamic peripheral immune landscapes during the AIT-initiation phase in venom allergy patients (VAP) versus pollen-allergic and healthy controls. Already at baseline, VAP exhibit altered abundances of several cell types, including classical monocytes (cMono), CD4<sup>+</sup> hybrid type 1-type 17 cells (Th1-Th17 or Th1/17) and CD8<sup>+</sup> counterparts (Tc1-Tc17 or Tc1/17). At 8-24 h following AIT launch in VAP, we identify a uniform AIT-elicited pulse of late-transitional/IL-10-producing B cells, IL-6 signaling within Th2 cells and non-inflammatory serum-IL-6 levels. Sequential induction of activation and survival protein markers also immediately occur. A disequilibrium between serum IL-6 and cMono in VAP baseline is restored at day seven following AIT launch. Our longitudinal analysis discovers molecular switches during initiation-phase insect-venom AIT that secure long-term outcomes. Trial number: NCT02931955.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2024-11-26
DOI
https://doi.org/10.1038/s41467-024-54684-2
Citations
8
Primary Topic
Allergic Rhinitis and Sensitization
Type
article
Field-Weighted Citation Impact
3.06

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study

Agnieszka Demczuk, Sylvie Delhalle, Oliver Hunewald, Jan Gutermuth et al.
8 citations
Nature Communications
Allergic Rhinitis and Sensitization
3.06
article

Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study

Agnieszka Demczuk, Sylvie Delhalle, Oliver Hunewald, Jan Gutermuth, Sebastian F. N. Bode, Wim Ammerlaan, Séverine Ciré, Aurélie Poli, Dimitrii Pogorelov, Antonio Cosma, Olivia Domingues, Fanny Hedin, Maria Konstantinou, Markus W. Ollert, Christophe Capelle, Joseph Longworth, Jorge Gonçalves, Ludger Klimek, M. Morisset, Léa Guyonnet, Ni Zeng, Ilse Weets, Lorie Neuberger-Castillo, Jacques Zimmer, Pinar Alper, Vladimı́r Beneš, Christiane Lehners‐Weber, Enrico Glaab, Ingrid Casper, Mohamed H. Shamji, Murilo Luiz Bazon, Fay Betsou, Guillem Montamat, Feng He, Alexandre Baron, Françoise Codreanu‐Morel, Dirk Brenner, Coralie L. Guérin, Dominique Revets, Paul Wilmes, Reinhard Schneider, Javier Ramiro‐Garcia, François Hentges, He Xin
article en
8 citations

Abstract

Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. The primary outcome of this observational study is the comprehensive immunological cellular characterization during the AIT initiation phase, whereas the secondary outcomes are the serological and Th2-cell-type-specific transcriptomic analyses. Here we apply a multilayer-omics approach to reveal dynamic peripheral immune landscapes during the AIT-initiation phase in venom allergy patients (VAP) versus pollen-allergic and healthy controls. Already at baseline, VAP exhibit altered abundances of several cell types, including classical monocytes (cMono), CD4<sup>+</sup> hybrid type 1-type 17 cells (Th1-Th17 or Th1/17) and CD8<sup>+</sup> counterparts (Tc1-Tc17 or Tc1/17). At 8-24 h following AIT launch in VAP, we identify a uniform AIT-elicited pulse of late-transitional/IL-10-producing B cells, IL-6 signaling within Th2 cells and non-inflammatory serum-IL-6 levels. Sequential induction of activation and survival protein markers also immediately occur. A disequilibrium between serum IL-6 and cMono in VAP baseline is restored at day seven following AIT launch. Our longitudinal analysis discovers molecular switches during initiation-phase insect-venom AIT that secure long-term outcomes. Trial number: NCT02931955.

Nature CommunicationsVol. 15(1)
Vrije Universiteit Brussel (BE), Inserm (FR), Institut Pasteur (FR), University of Freiburg (DE), Centre Hospitalier de Luxembourg (LU), University of Southern Denmark (DK), University of Luxembourg (LU), Universität Ulm (DE), Université Paris Cité (FR), University Medical Center Freiburg (DE), ETH Zurich (CH), Luxembourg Institute of Health (LU), Zentrum für Rhinologie und Allergologie (DE), Universitair Ziekenhuis Brussel (BE), European Molecular Biology Laboratory (DE), Imperial College London (GB), Université d'Angers (FR), Technical University of Munich (DE), Institut Curie (FR)
Integrated BioBank of Luxembourg, European Commission, Fonds National de la Recherche Luxembourg, International Council for Canadian Studies, Action LIONS Vaincre le Cancer, European Academy of Allergy and Clinical Immunology, HORIZON EUROPE Framework Programme
Life in Land
Openalex Percentile: Top 8%
Allergic Rhinitis and Sensitization
3.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.